AzentaAZTA
Recorded

Azenta 2026 Q4 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ4 2026Duration1 hr 0 minParticipants11

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Greetings and welcome to Azenta Fourth Quarter 2026 Fiscal Financial Results. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. As a reminder, this conference is being recorded Wednesday, November 11, 2026. I will now turn the conference call over to Yvonne Perron, Vice President, FP&A and Investor Relations.

Yvonne PerronVP of Financial Planning and Analysis and Investor Relations

Thank you, operator, and good morning, and welcome to everyone joining us today. We would like to welcome you to our earnings conference call for the fourth quarter of fiscal year 2026. Our fourth quarter earnings press release was issued yesterday after market and is available on our investor relations website located at investors.azenta.com, in addition to the PowerPoint slides and supplementary information that will be used during the prepared remarks today. I would like to remind everyone that during the course of the call, we will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our fiscal 2027 outlook, strategic initiatives, and recently announced transactions. Actual results may differ materially from those expressed or implied by those forward-looking statements.

Yvonne PerronVP of Financial Planning and Analysis and Investor Relations

I would refer you to the section of our earnings release titled Safe Harbor Statement, the Safe Harbor slide on the aforementioned PowerPoint presentation on our website, and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We undertake no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. We may refer to a number of non-GAAP financial measures, which are used in addition to and in conjunction with results presented in accordance with GAAP. We believe the non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with GAAP financial results and the reconciliation of GAAP measures, they provide an even more complete understanding of the Azenta business.

Yvonne PerronVP of Financial Planning and Analysis and Investor Relations

Non-GAAP measures should not be relied upon to the exclusion of the GAAP measures themselves. On the call with me today are Interim President and Chief Executive Officer, Dr. Martin Madaus, our Executive Vice President and Chief Financial Officer, Lawrence Lin, and Trey Martin, our President of Multiomics. We will begin the call with opening remarks from Martin and Trey, followed by Lawrence, who will provide a detailed review of our financial results and our outlook for fiscal year 2027. We will then take your questions at the end of the prepared remarks. With that, I would like to turn the call over to our interim CEO, Dr. Martin Madaus.

Martin MadausInterim President and CEO

Thank you, Yvonne, and good morning, everyone. Thank you for joining us. In August of this year, I assumed the role of Interim President and Chief Executive Officer after the departure of the previous CEO. We closed fiscal 2026 with good progress towards improving the business. The second half was significantly better than the first. Our goal is to deliver consistent performance quarter after quarter. For fiscal year 2027, we will convert opportunity into sustained growth and stronger operational performance. During Q4, we continued to drive the business forward without delay and advanced several major in-flight improvement initiatives impacting revenue and bottom line growth. I am pleased to tell you that our Q4 2026 revenue came in slightly better than expected. We are now seeing improvements in booking trends across the business. Expanded commercial coverage and a stronger operating focus have contributed to better execution of our opportunities.

Martin MadausInterim President and CEO

Now, the highlights for Q4 are another quarter of double digits year-over-year growth in the Sample Repository Services and the Consumables and Instruments businesses, improved performance across selected sequencing services, and continued growth in gene synthesis within Multiomics. We also took decisive restructuring actions to improve operating efficiency and return capital to shareholders through our stock repurchase program. These accomplishments in the face of many changes speak volumes about the committed leadership we have at Azenta. Now, three months into my role as interim CEO, I can clearly see a path to a higher performing organization. So, what does that mean specifically? We have a solid market leadership position in the SRS business, and there are market segments where we can be more successful to drive more profitable revenue growth. The focus is on commercial expansion.

Martin MadausInterim President and CEO

In the C&I business, we have differentiated capability in several market segments, and we can achieve more with commercial execution and also with new products. Both are within our control. Our Stores business has faced a market pullback and quality issues, but the products we offer are competitive and needed in the market. This created a drag on the SMS business performance in 2026 on both revenue and profitability. Now we are seeing that product quality is improving, booking trends are better, and we will be launching two new product lines at the end of fiscal year 2027 that are expected to support future growth. Our overall focus is straightforward. The top three priorities are profitable revenue growth, consistent execution of our initiatives, and targeted cost control to drive market expansions. Now, let me briefly speak about the Multiomics business, also called GENEWIZ.

Martin MadausInterim President and CEO

Following Trey Martin's arrival in April, we moved quickly to address organizational gaps and refocus the service offerings on high-growth sequencing services and gene synthesis, allowing us to better manage the transition away from the declining Sanger sequencing segment to other offerings. The difference between the first half of fiscal 2026 and the second half has been impressive. We are still in the middle of the Multiomics business evolution, but we saw encouraging booking trends in Q4. We recently announced two strategic deals in the gene synthesis space, which are intended to expand our participation in the growing AI-enabled drug discovery market and build a more competitive growth platform across our global lab network. So let me turn now to our fiscal 2026 performance, and Lawrence will provide the detailed financial review later. For fiscal 2026, organic revenue grew 2% with an adjusted EBITDA margin of 9.4%.

Martin MadausInterim President and CEO

Revenue exceeded our latest outlook, while profitability was broadly in line with our most recent guidance. Importantly, performance improved in the second half, giving us a better momentum as we enter now fiscal year 2027. The improvement reflects better commercial execution, stronger performance in North America Multiomics, and progress against several of the operational actions we put in place during the year. Sample Management Solutions delivered low single-digit organic growth, supported by the strength in our much faster-growing recurring revenue businesses, which are biorepositories and Consumables and Instruments. Automated Stores faced major headwinds in 2026, mainly from constrained customer capital spending. Multiomics also delivered low single-digit organic growth above our outlook. While performance was uneven during the year, we saw significant improvement in the second half in North America as the actions we took to strengthen execution began to produce results.

Martin MadausInterim President and CEO

China delivered another strong year, and Europe also performed well, demonstrating the value of our global presence and our ability to apply different commercial and operating approaches across the geographies. Azenta has a leadership position in Sample Repository Services with profitable recurring revenue from our core storage business. We continue to expand the biorepositories business through high customer focus, deep workflow integration, and our ability to expand into new end markets. Automated storage remains an important business with strong competitive products and attractive long-term opportunity. Fiscal 2026 performance was below our expectations, reflecting both customer capital constraints and execution challenges. Our assessment indicates that the issues we experienced in 2026 can be solved. We are cautiously optimistic now based on much better booking trends and also improvements in our quality metrics. Multiomics represents one of Azenta's compelling near and long-term growth opportunities.

Martin MadausInterim President and CEO

Our synthesis business is performing well, with particular strength in China and continued solid performance in Europe. GENEWIZ scientific expertise, our global reach, established customer relationships provide a strong platform for expansion into adjacent genomic workflows. The replacement of Sanger sequencing by other technologies we offer now continued in Q4, particularly in North America. Under Trey's leadership, we have launched a comprehensive effort to address those challenges and reposition GENEWIZ towards faster-growing, higher-value genomic discovery and clinical workflows. Our objective is clear: strengthen GENEWIZ's competitive position, return Multiomics to a sustainable and consistent growth, and build a more scalable, profitable business. Our approach has three components for that. First, we are creating a stronger operating foundation. The restructuring of the U.S. laboratory footprint will create a leaner, more focused model designed to improve capacity utilization and profitability.

Martin MadausInterim President and CEO

It also provides a more scalable platform for introducing new genomic offerings while maintaining our commitment to quality and turnaround time. Second, we're adding differentiated capabilities. Our agreement with Elegen expands our position in rapid, high-purity DNA synthesis, while the acquisition of SynPlexity adds ultra-high throughput pooled gene synthesis. Together, these capabilities are intended to move GENEWIZ into faster-growing, higher-value parts of the genomic discovery workflow. Third, we will use GENEWIZ's established scientific expertise, our customer relationships, and our global commercial infrastructure to bring these capabilities to market and scale them effectively. We believe that this combination of a stronger operating model, differentiated technology, and our global commercial reach can position GENEWIZ as a broader partner across the genomic discovery workflow.

Martin MadausInterim President and CEO

I will now turn this over to Trey Martin, the President of Multiomics, to explain how Elegen and SynPlexity strengthen our position across the genomic discovery workflow and how we plan to bring these capabilities to customers. Trey brings more than 30 years of industry experience. Trey is an elite executive with a proven track record of bringing novel gene synthesis technologies to market, notably at Integrated DNA Technologies at Danaher.

Trey MartinPresident of Multiomics

Thank you, Martin, and good morning, everyone. As Martin described, we are strengthening the foundation of Multiomics while expanding GENEWIZ into higher-value areas of genomic discovery. Elegen's proprietary technology strengthens the DNA build step. Under our exclusive licensing agreement, which is subject to specified rights and exceptions, GENEWIZ plans to manufacture and commercialize products using Elegen's cell-free DNA synthesis platform. By producing high-purity DNA without the conventional cloning step, this technology is designed to simplify the customer workflows and address a key bottleneck to accelerate the move from digital design to discovery testing. SynPlexity adds a complementary capability, the ability to produce thousands of full-length gene designs in parallel. This proprietary gene synthesis technology allows researchers to explore large design spaces in a single library, moving beyond the traditional gene-by-gene workflows and into very high-throughput, low-cost discovery applications.

Trey MartinPresident of Multiomics

These capabilities further position GENEWIZ to participate in the rapidly growing use of AI-enabled drug discovery workflows. AI is increasing the number and complexity of biological designs researchers can evaluate, but those digital antibody designs still need to be built, tested, and validated experimentally to move the models forward. GENEWIZ connects the AI-generated designs with the wet lab through synthesis, sequencing, and validation, helping customers accelerate the design, build, test, learn cycle. The new technologies from Elegen and SynPlexity come at a perfect time when the market is showing strong demand for gene and antibody synthesis products due to the accelerating investment in AI-enabled drug discovery. We believe they will further position GENEWIZ as a competitively differentiated player in the space. Our top priority is to integrate, fully commercialize the consolidated portfolio, and scale these technologies globally. Importantly, we are not building the commercial platform from the ground up.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day